ABSTRACT
Background: end stage renal disease [ESRD] is now considered a prototypical situation of chronic inflammatory state. Inflammation is thought to contribute to initiation and aggravation of atherosclerosis through a process predominantly mediated by adhesion molecules. The expression of soluble intercellular cell adhesion molecule 1 [slCAM-1] and soluble vascular cell adhesion molecule 1 [sVCAM-1] on the cell surface is upregulated by inflammation. The aims of this study were to measure slCAM-1 and s VCAM-1 in sera of normotensive and hypertensive CRF patients under hemodialysis [HD] and compare them with healthy controls. Also, the effect of dialyzer on these molecules was studied in a single uncomplicated HD session
Methods: we evaluated 40 patients with CRF under treatment with regular HD, they were classified into two groups: Group I: 20 hypertensive patients [12 males and 8 females] aged 30+/-8.2 years, Group II: 20 normotensive patients [11 males and 9 females] aged 34.0+/-16.8 years, ten healthy volunteers constituted group Ill [5 males and 5 females], aged 33.0+/-10.2 years. Blood samples were taken from all patients 4 times, at start and at the end of HD session and from the inlet and exit lines of the dialyzer, 5ml of blood were collected from controls. slCAM-1 and sVCAM-1 were measured by ELISA
Results: we found that there was no significant difference in slCAM-1 and sVCAM-l between group land group Jibe/ore and after the dialyzer [p >0.05]. There was a highly significant difference in sVCAM-l between patients and controls. [p<0.001], while there was no significant difference between patients of group I and group 11 [p>0.05], we found no statistically significant difference in slCAM-1 in all studied groups [p>0.05]
Conclusions: no influence of HD membrane on the levels of s/CAM-1 and sVCAM-1, the elevated sVCAM-1 compared with controls. In patients on maintenance HD. may activate immunocompetent cells. The presence of hypertension doesn't add impact to slCAM-1 and sVCAM-1 levels in CRF patients
ABSTRACT
Background: granzymes [Gz] A and B are recently discovered mediators in asthma and other inflammatory airway diseases and showed minimal suppression by corticosteroids
Aim of the study: to see if there is any difference in both granzymes in induced sputum samples between steroid sensitive and steroid resistant asthmatics
Methods: both granzymes were measured by ELISA assay in induced sputum samples from 27 steroid sensitive [SS] and I 8 steroid resistant [SR] asthmatics plus 15 normal controls
Results: Gz A was significantly higher in SR than SS patients and controls [p<0. 05], but was insignificantly different between SS patients and controls [p>0.05]. Gz B was significantly higher in SR patients than SS patients and controls [p<0.05]. No significant difference was seen between males and females of the studied groups [p >0.05 for all].Significant negative correlations were found between both granzymes and FEVJ% predicted in both SS and SR groups [r=-0.85, r=-0.49for Gz A and r= -0.87, r= 0. 7 for Gz B respectively]. A significant positive correlation was found between the two granzymes in both patient groups [r=0.93 and 0.63 for SS and SR patients respectively]
Conclusion: granzymes A and B are released in the airways of asthmatic patients and could have an important role in asthmatic airway inflammation especially in steroid resistant cases and might play a role in this resistance